The fact that MEK inhibitors only have modest clinical efficacy in RAS mutant cancers compared to BRAF mutant cancers is mainly due to the relief of ERK-mediated negative feedback and the BRAF, CRAF-dependent reactivation of MEK 67, 68. Here, MAPK1 is linked to cancer.